Peter Kaatsch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6494124/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of era of diagnosis on causeâ€specific late mortality among 77 423 fiveâ€year European survivors of childhood and adolescent cancer: The <scp>PanCareSurFup</scp> consortium. International Journal of Cancer, 2022, 150, 406-419.	5.1	11
2	Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. JMIR Research Protocols, 2021, 10, e21851.	1.0	9
3	Managing a Pan-European Consortium on Late Effects among Long-Term Survivors of Childhood and Adolescent Cancer—The PanCareLIFE Project. International Journal of Environmental Research and Public Health, 2021, 18, 3918.	2.6	8
4	Mental health and healthâ€related quality of life in preschoolâ€aged childhood cancer survivors. Results of the prospective cohort study ikidSâ€OEVA. Pediatric Blood and Cancer, 2021, 68, e29039.	1.5	5
5	Identification of Genetic Predispositions Related to Ionizing Radiation in Primary Human Skin Fibroblasts From Survivors of Childhood and Second Primary Cancer as Well as Cancer-Free Controls: Protocol for the Nested Case-Control Study KiKme. JMIR Research Protocols, 2021, 10, e32395.	1.0	8
6	Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers, 2021, 13, 4598.	3.7	8
7	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics Journal, 2020, 20, 294-305.	2.0	28
8	Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European Journal of Cancer, 2020, 138, 212-224.	2.8	31
9	Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief, 2020, 32, 106227.	1.0	2
10	Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study. Gut, 2020, , gutjnl-2020-322237.	12.1	5
11	Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. European Journal of Cancer, 2019, 117, 71-83.	2.8	12
12	Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study. Neuro-Oncology, 2019, 21, 1069-1081.	1.2	16
13	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Research Protocols, 2019, 8, e11868.	1.0	10
14	The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries. European Journal of Epidemiology, 2018, 33, 335-349.	5.7	38
15	Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe. Journal of the National Cancer Institute, 2018, 110, 183-194.	6.3	38
16	Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. BMC Cancer, 2018, 18, 930.	2.6	13
17	PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. European Journal of Cancer, 2018, 103, 227-237.	2.8	41
18	The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer. European Journal of Cancer, 2018, 103, 238-248.	2.8	30

Peter Kaatsch

#	Article	IF	CITATIONS
19	Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe. Journal of the National Cancer Institute, 2018, 110, 649-660.	6.3	36
20	Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR Research Protocols, 2018, 7, e10824.	1.0	14
21	Background gamma radiation and childhood cancer in Germany: an ecological study. Radiation and Environmental Biophysics, 2017, 56, 127-138.	1.4	25
22	Return and Disclosure of Research Results: Parental Attitudes and Needs Over Time in Pediatric Oncology. Journal of Pediatrics, 2017, 191, 232-237.	1.8	5
23	Home pesticide exposures and risk of childhood leukemia: Findings from the childhood leukemia international consortium. International Journal of Cancer, 2015, 137, 2644-2663.	5.1	108
24	Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care. European Journal of Cancer, 2015, 51, 1203-1211.	2.8	98
25	Childhood cancer survivor cohorts in Europe. Acta Oncológica, 2015, 54, 655-668.	1.8	97
26	Local radiation dose and solid second malignant neoplasms after childhood cancer in Germany: a nested case–control study. Radiation and Environmental Biophysics, 2014, 53, 485-493.	1.4	11
27	Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 35-47.	10.7	799
28	Epidemiology of childhood cancer. Cancer Treatment Reviews, 2010, 36, 277-285.	7.7	769
29	Survival of European children and young adults with cancer diagnosed 1995–2002. European Journal of Cancer, 2009, 45, 992-1005.	2.8	442
30	Case–control study on childhood cancer in the vicinity of nuclear power plants in Germany 1980–2003. European Journal of Cancer, 2008, 44, 275-284.	2.8	91
31	Time trends of cancer incidence in European children (1978–1997): Report from the Automated Childhood Cancer Information System project. European Journal of Cancer, 2006, 42, 1961-1971.	2.8	117
32	International Classification of Childhood Cancer, third edition. Cancer, 2005, 103, 1457-1467.	4.1	1,175
33	Epidemiology of pediatric tumors of the central nervous system. Expert Review of Neurotherapeutics, 2002, 2, 469-479.	2.8	8
34	Secondary neoplasms subsequent to Berlin-Frankfurt-MuÌ^nster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood, 2000, 95, 2770-2775.	1.4	247